FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387110147> ?p ?o ?g. }

• W4387110147 endingPage "576" @default.
• W4387110147 startingPage "567" @default.
• W4387110147 abstract "The classic, Philadelphia chromosome-negative (Ph−) myeloproliferative neoplasms (MPN) are characterized by universal activation of Janus kinase (JAK)-signal transducer and activator of transcription (STAT) signaling, and the JAK1/2 inhibitor ruxolitinib has shown broad clinical activity across myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). Ruxolitinib is currently approved by regulatory authorities for the treatment of MF and hydroxyurea (HU)-resistant/intolerant PV. Although the cornerstone of management of MF, ruxolitinib has some limitations, which has led to interest in developing other JAK inhibitors, as well as ruxolitinib-based rational combinations. Problems with ruxolitinib include on-target anemia and thrombocytopenia, as well as eventual loss of clinical efficacy. Additionally, while ruxolitinib improves survival of patients with MF, its disease-modifying effects, as evidenced by improvement in bone marrow fibrosis and reduction of the mutant allele burden, appear modest; indeed, this could be a feature of all JAK inhibitors currently in the clinic. Furthermore, there is no evidence that JAK inhibitors prevent or delay disease progression and leukemic transformation. Fedratinib, a JAK2 inhibitor with an efficacy profile similar to that of ruxolitinib, is also approved for the treatment of MF. Currently, fedratinib is primarily used second-line, after ruxolitinib failure, a challenging clinical scenario. Momelotinib, a JAK1/2 and activin receptor type 1 (ACVR1) inhibitor, is being developed in the second-line setting in symptomatic, anemic patients with MF, while development efforts for pacritinib, a relatively nonmyelosuppressive JAK2 inhibitor, are focused on MF patients with severe thrombocytopenia. In HU-resistant/intolerant PV, the benefits of ruxolitinib in terms of hematocrit control, spleen shrinkage, and symptom improvement are durable, and the drug may decrease the incidence of thromboembolic events. Finally, activating mutations in CSF3R and molecular rearrangements that activate JAK-STAT, such as PCM1-JAK2, render certain rare, atypical MPN, e.g., chronic neutrophilic leukemia (CNL) and myeloid/lymphoid neoplasms with eosinophilia (MLNEo) sensitive to ruxolitinib." @default.
• W4387110147 created "2023-09-28" @default.
• W4387110147 creator A5013173470 @default.
• W4387110147 creator A5085521139 @default.
• W4387110147 date "2023-01-01" @default.
• W4387110147 modified "2023-09-28" @default.
• W4387110147 title "JAK Inhibitors for the Management of Myeloproliferative Neoplasms" @default.
• W4387110147 cites W1503482160 @default.
• W4387110147 cites W1534089060 @default.
• W4387110147 cites W1918141746 @default.
• W4387110147 cites W1979832242 @default.
• W4387110147 cites W1980568348 @default.
• W4387110147 cites W1980972742 @default.
• W4387110147 cites W1996789097 @default.
• W4387110147 cites W1999000517 @default.
• W4387110147 cites W2049145190 @default.
• W4387110147 cites W2049965335 @default.
• W4387110147 cites W2051649863 @default.
• W4387110147 cites W2057360098 @default.
• W4387110147 cites W2063756127 @default.
• W4387110147 cites W2079800026 @default.
• W4387110147 cites W2086511628 @default.
• W4387110147 cites W2087700674 @default.
• W4387110147 cites W2115351357 @default.
• W4387110147 cites W2121743767 @default.
• W4387110147 cites W2122395736 @default.
• W4387110147 cites W2123633897 @default.
• W4387110147 cites W2126532431 @default.
• W4387110147 cites W2138709799 @default.
• W4387110147 cites W2143057570 @default.
• W4387110147 cites W2144664431 @default.
• W4387110147 cites W2150100099 @default.
• W4387110147 cites W2155046477 @default.
• W4387110147 cites W2157066112 @default.
• W4387110147 cites W2157694607 @default.
• W4387110147 cites W2158669800 @default.
• W4387110147 cites W2159533809 @default.
• W4387110147 cites W2199810342 @default.
• W4387110147 cites W2289879004 @default.
• W4387110147 cites W2294536664 @default.
• W4387110147 cites W2345645288 @default.
• W4387110147 cites W2405712018 @default.
• W4387110147 cites W2418937816 @default.
• W4387110147 cites W2493211728 @default.
• W4387110147 cites W2511586498 @default.
• W4387110147 cites W2514287253 @default.
• W4387110147 cites W2529276663 @default.
• W4387110147 cites W2544907814 @default.
• W4387110147 cites W2547176669 @default.
• W4387110147 cites W2559562829 @default.
• W4387110147 cites W2566974890 @default.
• W4387110147 cites W2570291199 @default.
• W4387110147 cites W2577607829 @default.
• W4387110147 cites W2584119988 @default.
• W4387110147 cites W2586215211 @default.
• W4387110147 cites W2589237569 @default.
• W4387110147 cites W2598479043 @default.
• W4387110147 cites W2608896188 @default.
• W4387110147 cites W2614950548 @default.
• W4387110147 cites W2616315621 @default.
• W4387110147 cites W2617895748 @default.
• W4387110147 cites W2622547803 @default.
• W4387110147 cites W2731255636 @default.
• W4387110147 cites W2731573311 @default.
• W4387110147 cites W2744415080 @default.
• W4387110147 cites W2749657249 @default.
• W4387110147 cites W2754551124 @default.
• W4387110147 cites W2759277150 @default.
• W4387110147 cites W2768672347 @default.
• W4387110147 cites W2773899764 @default.
• W4387110147 cites W2778275419 @default.
• W4387110147 cites W2788549310 @default.
• W4387110147 cites W2790003237 @default.
• W4387110147 cites W2791240656 @default.
• W4387110147 cites W2796704538 @default.
• W4387110147 cites W2885542040 @default.
• W4387110147 cites W2901078409 @default.
• W4387110147 cites W2917089748 @default.
• W4387110147 cites W2935908830 @default.
• W4387110147 cites W2944967047 @default.
• W4387110147 cites W2946901694 @default.
• W4387110147 cites W2988253820 @default.
• W4387110147 cites W2990043937 @default.
• W4387110147 cites W2991379201 @default.
• W4387110147 cites W2996087467 @default.
• W4387110147 cites W2997715942 @default.
• W4387110147 cites W3001173748 @default.
• W4387110147 cites W3001373379 @default.
• W4387110147 cites W3003423609 @default.
• W4387110147 cites W3005898823 @default.
• W4387110147 cites W3008023739 @default.
• W4387110147 cites W3009670005 @default.
• W4387110147 cites W3015869041 @default.
• W4387110147 cites W3085980128 @default.
• W4387110147 cites W3095758083 @default.
• W4387110147 cites W3096130022 @default.
• W4387110147 cites W3096383113 @default.
• W4387110147 cites W3096496248 @default.

• next